CN107242551A - A kind of cancer rehabilitation type Medical Nutritional composition and preparation method thereof - Google Patents
A kind of cancer rehabilitation type Medical Nutritional composition and preparation method thereof Download PDFInfo
- Publication number
- CN107242551A CN107242551A CN201710545346.3A CN201710545346A CN107242551A CN 107242551 A CN107242551 A CN 107242551A CN 201710545346 A CN201710545346 A CN 201710545346A CN 107242551 A CN107242551 A CN 107242551A
- Authority
- CN
- China
- Prior art keywords
- medical nutritional
- nutritional composition
- accounts
- component
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 66
- 201000011510 cancer Diseases 0.000 title claims abstract description 66
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 25
- 239000003094 microcapsule Substances 0.000 claims abstract description 22
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 14
- 230000035764 nutrition Effects 0.000 claims abstract description 12
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 12
- 230000033228 biological regulation Effects 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 9
- 230000002496 gastric effect Effects 0.000 claims abstract description 9
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000021323 fish oil Nutrition 0.000 claims abstract description 8
- 235000021388 linseed oil Nutrition 0.000 claims abstract description 8
- 239000000944 linseed oil Substances 0.000 claims abstract description 8
- 108010035532 Collagen Proteins 0.000 claims abstract description 7
- 102000008186 Collagen Human genes 0.000 claims abstract description 7
- 229920001436 collagen Polymers 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 229920001202 Inulin Polymers 0.000 claims abstract description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 6
- 229940029339 inulin Drugs 0.000 claims abstract description 6
- 239000003921 oil Substances 0.000 claims abstract description 6
- 235000019198 oils Nutrition 0.000 claims abstract description 6
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 5
- 230000001900 immune effect Effects 0.000 claims abstract description 5
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000001259 polydextrose Substances 0.000 claims abstract description 4
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 4
- 229940035035 polydextrose Drugs 0.000 claims abstract description 4
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract 2
- 238000009472 formulation Methods 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims description 19
- 241000208340 Araliaceae Species 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 9
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000004626 polylactic acid Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 241000251511 Holothuroidea Species 0.000 claims description 3
- 102000004407 Lactalbumin Human genes 0.000 claims description 3
- 108090000942 Lactalbumin Proteins 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 241000255789 Bombyx mori Species 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 238000007493 shaping process Methods 0.000 claims description 2
- 235000019197 fats Nutrition 0.000 claims 2
- 239000004375 Dextrin Substances 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 208000000655 Distemper Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 244000269722 Thea sinensis Species 0.000 abstract description 3
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 abstract description 2
- 235000017647 Brassica oleracea var italica Nutrition 0.000 abstract description 2
- 229920002307 Dextran Polymers 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract description 2
- 235000009569 green tea Nutrition 0.000 abstract description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 229960002743 glutamine Drugs 0.000 abstract 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 abstract 1
- 239000000047 product Substances 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 10
- 230000013872 defecation Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 208000034657 Convalescence Diseases 0.000 description 7
- 208000007502 anemia Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 206010006895 Cachexia Diseases 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229920000747 poly(lactic acid) Polymers 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 235000010413 sodium alginate Nutrition 0.000 description 4
- 239000000661 sodium alginate Substances 0.000 description 4
- 229940005550 sodium alginate Drugs 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000028399 Critical Illness Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 108010071690 Prealbumin Proteins 0.000 description 3
- 102000007584 Prealbumin Human genes 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000190633 Cordyceps Species 0.000 description 2
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 239000000976 ink Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- AHRFRRASJMTTQU-UHFFFAOYSA-N 6-methyl-2,2-dioxooxathiazin-4-one;potassium Chemical compound [K].CC1=CC(=O)NS(=O)(=O)O1 AHRFRRASJMTTQU-UHFFFAOYSA-N 0.000 description 1
- 244000308180 Brassica oleracea var. italica Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 244000038022 Chenopodium capitatum Species 0.000 description 1
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- -1 sucrose fatty ester Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind of cancer rehabilitation type Medical Nutritional composition and preparation method thereof, and there is provided the Medical Nutritional product including a kind of component containing nutrition, herbal component, immunological regulation component, gastrointestinal regulation component.Nutrition component includes protein source, fat source and carbohydrate source；Herbal component is selected from ginseng, Cordyceps militaris, jujube, green tea, broccoli；Immunological regulation component selects biologically active peptide, the unrighted acids of ω 3 (linseed oil, fish oil), collagen, glutamine, MCT Oil, branched-chain amino acid, β yeast dextrans；Gastrointestinal regulation component is selected from glutamine, polydextrose, inulin, FOS, xylo-oligosaccharide.Product provided by the present invention, using dissolution formulation technology, the processing of micro-capsule embedding techniques, can alleviate cancer patient's postoperative syndrome, promote cancer patient's rehabilitation, improve life quality, extending life cycle.
Description
Technical field
The invention belongs to Medical Nutritional field, and in particular to the Medical Nutritional composition and its system of a kind of promotion cancer rehabilitation
Preparation Method.
Background technology
Cancer has turned into first of the human diseases cause of the death, and its incidence of disease constantly rises, global cancer new cases in 2008
Rise to 14,090,000 within 12700000,2013, it is contemplated that to the year two thousand thirty, cancer new cases are up to 26,000,000.According to 2017 Cancer in China
Statistics shows that China's cancer new cases 429.2 ten thousand in 2015 account for the total number of the infected a quarter in the world, daily about 1.2
Ten thousand new cancer cases, average minute clock is newly-increased 8.People's all one's life P is 36%, and lung cancer is still China's pathogenesis of cancer
Rate, the death rate first, thyroid cancer incidence is in rising trend.
Cancer is simultaneously not equal to incurable disease, and the World Health Organization in 2006 announces, and cancer is a kind of chronic disease, Britain, Germany etc.
Developed country, 5 years survival rates of cancer are substantially all more than 70%, wherein Japan, Australia, Canada are up to more than 80%.
However, Cancer in China five year survival rate is only 30.9%, by contrast, China's room for promotion is huge！Newest medical statistics shows,
Complex treatment to cancer concentrates on treatment phase (such as chemicotherapy, operation), and only 37% patient carries out convalescence treatment, and
85% cancer patient is dead in convalescence.
Cancer patient's convalescence syndrome is mainly shown as：Immunosupress, anaemia, cachexia, functions of intestines and stomach disorder, cancer
Potential recurrent.However, convalescence product concentrates on raising immunity product or nutritional supplementation at present, lack and be directed to cancer rehabilitation
The product of phase syndrome.Immunity or extra-nutrition are individually improved, the integration requirement of convalescence cancer patient can not be met.
It is contemplated that a kind of Medical Nutritional composition for meeting cancer rehabilitation phase integration requirement of exploitation, the product can mended
While filling nutrition, improve the symptoms such as cancer patient hypoimmunity, anaemia, cachexia, gastrointestinal barrier be impaired.Improve cancer health
Multiple phase syndrome, promotes cancer patient's rehabilitation, improves life quality, extending life cycle.
The content of the invention
The purpose of the present invention is to propose to a kind of Medical Nutritional composition for improving cancer rehabilitation phase syndrome and its preparation side
Method.
The concrete technical scheme for realizing above-mentioned purpose of the present invention is：
A kind of cancer rehabilitation type Medical Nutritional composition is developed, contains nutrition there is provided one kind for cancer rehabilitation phase syndrome
Medical Nutritional product including component, herbal component, immunological regulation component, gastrointestinal regulation component.
The Medical Nutritional composition, nutrition component includes protein source, fat source and carbohydrate source, with composition
Gross mass meter, protein accounts for 10-35%, and lipid accounts for 2-20%, and carbohydrate accounts for 40-55%.Protein be selected from lactalbumin,
One or more in collagen；One or more of the fat in medium chain fatty acid, fish oil, linseed oil；Carbon aquation
One or more of the compound in inulin, polydextrose.Characterized in that, in terms of composition gross mass, collagen accounts for 10-
15%, lactalbumin accounts for 10-15%, and ginseng accounts for 0.5-10%, and Cordyceps militaris accounts for 0.5-8%, and Tea Polyphenols accounts for 0.5-6%, and ω -3 is not
Saturated fatty acid accounts for 5-20%, and biologically active peptide is (in cordyceps sinensis peptide, ginseng peptide, collagen peptide, silkworm chrysalis peptide, donkey-hide gelatin peptide, sea cucumber peptide
One or more) account for 5-20%, glutamine accounts for 2-10%, and MCT Oil accounts for 1-6%, and branched-chain amino acid is accounted for
1-6%, β-yeast dextran account for 0.5-5%, and inulin accounts for 3-10%.
Brief description of the drawings
Fig. 1 is the local flavor profile of cancer rehabilitation type Medical Nutritional composition；
Fig. 2 is each test group mouse carbonic clearance index.
Embodiment
The main inducing of cancer rehabilitation phase syndrome, including cancer cell infringement, treatment side effect, are embodied in, with machine
Immunosupress, anaemia based on body metabolic disorder, cachexia, gastrointestinal dysfunction.The body of cancer rehabilitation phase syndrome is special
Levy and clinical manifestation is shown in Table 1.
1 cancer rehabilitation phase of table syndrome
Based on cancer rehabilitation phase syndrome described in table 1, the Medical Nutritional composition of designed exploitation per raw material simply, all
Based on improving cancer rehabilitation phase symptom.The formula composition and applicability are shown in Table 2.
The cancer rehabilitation type Medical Nutritional of table 2 is formulated
(note：Each component can be in cross-distribution difference in functionality component)
The Medical Nutritional composition, technology characteristics are that, stability poor to dissolubility is poor, smell is poor, poor taste original
Material, carries out micro-capsule embedding process, instant PROCESS FOR TREATMENT, by the auxiliary material needed for all raw material and preparations shaping, according to weight
First mixed than close raw material, gradient mixing step by step is proceeded by from the raw material of lighter in weight, sieving afterwards is mixed, according to medicine
Preparation conventional method makes clinically suitable various preparations.
A kind of optimal technical scheme prepared the following is Medical Nutritional composition of the present invention：
1st, the preparation of microcapsules：(1) preparation of ginseng microcapsule powder：PLA is dissolved among chloroformic solution, 2h is stirred,
Cross 0.22um filter membrane；Ginseng pulverate is dissolved in methanol aqueous solution, magnetic agitation for a period of time, is added drop-wise to the chloroform of PLA
In solution, stirring is sufficiently mixed uniformly to the two, forms suspension；Continue under conditions of stirring, the suspension is added to
In well mixed Arabic gum and poly-vinyl alcohol solution, it is more uniform that ultrasound is allowed to mixing；1.5- is heated at 70-80 DEG C
2h, fully volatilizees to chloroform, obtains the suspension of micro-capsule；40ml distilled waters are added, 3h is stirred；By microcapsule suspension distilled water
Wash and centrifuge, in triplicate, then with distilled water micro-capsule has been shaken and wall built-up；Micro-capsule is spray-dried, ginseng PLA is obtained
The dry powder of micro-capsule.(2) preparation of cordyceps sinensis peptide microcapsule powder：Chitosan is dissolved in 1% acetum, anhydrous calcium chloride stirring is added equal
It is even.The sodium alginate aqueous solution of another preparation 3%, it is 3: 1 to make compound wall materialses chitosan and sodium alginate ratio, in sodium alginate water
Cordyceps sinensis peptide is added in solution, makes its final concentration of 40mg/L, the sodium alginate soln of the peptide containing cordyceps sinensis is slowly dropped in equal volume
Chitosan calcium chloride solution in, 50 DEG C of water-baths, and be transferred to pH5.0 with acetic acid are stirred continuously, water-bath are removed after 20min,
4000r/min centrifuges 15min, and sediment for several times, is drying to obtain micro-capsule powder by washing in 50 DEG C of baking ovens.(3) linseed oil,
Fish oil, the microcapsule powder of MCT Oil are commercially available.
2nd, the preparation of instant powder：(1) preparation of Cordyceps militaris instant powder：Cordyceps mycelium is dried, crushed, sieve after it is molten
Yu Shuizhong, successively thereto addition maltodextrin liquid, cycloheptaamylose liquid, glycerin monostearate liquid, sucrose fatty ester liquid,
Sodium carboxymethylcellulose liquid then stirs 5-10 minutes into the Cordyceps militaris aqueous solution, is spray-dried to obtain Cordyceps militaris instant powder.Match somebody with somebody
Square ratio is：Maltodextrin 20-25%, cycloheptaamylose 2-3.5%, glycerin monostearate 0.2-0.5%, sucrose-fatty
Ester 2-6%, sodium carboxymethylcellulose 10-15%.(2) linseed oil, fish oil instant powder are commercially available.
The beneficial effects of the present invention are：
1st, product proposed by the present invention is directed to cancer rehabilitation phase syndrome, can alleviate convalescence cancer patient's immunity low
Under, the disorder of anaemia, cachexia, functions of intestines and stomach, the symptom complex such as cancer return.
2nd, the product component containing nutrition, herbal component, immunological regulation component, gastrointestinal regulation component, from nutrition treatment, in
Doctor such as nurses one's health, treated both principal and secondary aspect of disease at the multi-angle selected raw material.
3rd, the product uses instant technology, micro-capsule embedding techniques, produces that stability is high, dissolubility is good, sensory experience
Good Medical Nutritional preparation.
4th, the product is debugged through strict organoleptic properties, and smell delicate fragrance, sour-sweet degree are moderate, and cancer patient orally complies with
By force.
5th, the product completes physicochemical, functional evaluation, carries out study on the stability, can stablize preserve 24 at room temperature
Individual month.Tested through zoopery or human experiment, it was demonstrated that the product can improve immunity, improve Anemia, nutrition shape
Condition, improves gastrointestinal function.
Following examples are used to illustrate the present invention, but are not limited to the scope of the present invention.
Embodiment 1：Suitable for the Medical Nutritional composition of cancer postoperative reparation phase.
The postoperative reparation phase is to complete operation or chemicotherapy, and the stage in 2 years, the subject matter of this stage cancer patients is to exempt from
Epidemic disease power is low, anaemia, intestines and stomach are impaired, chemicotherapy surgery side effect.Product described in the present embodiment is directed to problem above, selected each
Component raw material, formula is shown in Table 3.
Table 3：The Medical Nutritional composite formula of cancer postoperative reparation phase
Above raw material removes ginseng microcapsule powder, cordyceps sinensis peptide, and other raw materials can be bought by market and be obtained.Product preparation process
Method is as follows：
1) preparation of ginseng microcapsule powder：PLA is dissolved among chloroformic solution, 2h is stirred, 0.22um filter membrane is crossed；
Ginseng pulverate is dissolved in methanol aqueous solution, magnetic agitation for a period of time, is added drop-wise in the chloroformic solution of PLA, stirring to two
Person is sufficiently mixed uniformly, forms suspension；Continue under conditions of stirring, the suspension is added to well mixed Arab
In glue and poly-vinyl alcohol solution, it is more uniform that ultrasound is allowed to mixing；1.5-2h is heated at 70-80 DEG C, is fully volatilized to chloroform,
Obtain the suspension of micro-capsule；40ml distilled waters are added, 3h is stirred；Microcapsule suspension is washed and centrifuged with distilled water, three are repeated
It is secondary, then micro-capsule has been shaken and wall built-up with distilled water；Micro-capsule is spray-dried, the dry powder of ginseng Polylactic Acid Microspheres Containing is obtained.
2) preparation of cordyceps polypeptide：Fruiting bodies of cordyceps militaris is subjected to ultramicro grinding, distilled water regulation substrate quality is added dense
Spend for 50mg/ml, 95 DEG C of temperature, stir 15min, after cool to 75 DEG C, add bromelain 2%, hydrolyze 3h, hydrolysis knot
Beam, boiling water bath 15min enzymolysis reactions.Centrifuging and taking supernatant.The activated carbon of addition 0.5%, 45 DEG C of conditions in supernatant
Lower decolouring 30min, after decolouring terminates, centrifuging and taking supernatant.Gained supernatant is collected gained and filtered by 5000D ultrafiltration membrane treatments
Liquid, concentration, spray drying is produced.
3) above microcapsule powder and each solid material are weighed, is first mixed than close raw material according to weight, from lighter in weight
Raw material proceeds by gradient mixing step by step, crosses 40 mesh sieves, is mixed, be packed as under D grades of gnotobasis using three-dimensional motion mixer
15g/ bags.
Embodiment 2：Suitable for the steady convalescent Medical Nutritional composition of cancer.
Steady convalescence is to spend the postoperative reparation phase, and body tends to the stage of normal healthy level, this stage cancer patients
Subject matter be hypoimmunity, gastrointestinal absorption obstacle, the potential recurrent of cancer.Product described in the present embodiment is asked for more than
Topic, selected each component raw material, formula is shown in Table 4.
Product preparation process be the same as Example 1.
Table 4：The steady convalescent Medical Nutritional composite formula of cancer
| Component | Percentage by weight (%) |
| Collagen | 15 |
| Cordyceps sinensis peptide | 3 |
| Sea cucumber peptide | 3 |
| Fish oil powder | 5 |
| Linseed oil microcapsule powder | 5 |
| Broccoli | 6 |
| Ginseng | 5 |
| Green tea | 5 |
| Inulin | 5 |
| Polydextrose | 47.9 |
| 3,4-Dihydro-6-methyl-1,2,3-oxathiazin-4-one 2,2-dioxide potassium salt：Malic acid | 0.1 |
Embodiment 3 is applied to the Medical Nutritional composition of cancer critical illness phase
The subject matter of critical illness cancer patient is immunosupress, cachexia (muscle consumption, body weight rapid drawdown), it is disorderly to be metabolized
Disorderly, gastrointestinal absorption obstacle.Product described in the present embodiment is directed to problem above, and selected each component raw material, formula is shown in Table 5.
Table 5：The Medical Nutritional composite formula of cancer critical illness phase
The flavor evaluation of the cancer rehabilitation type Medical Nutritional composition of experimental example 1
Alimentation composition sample 15g in embodiment 1,2,3 is weighed respectively, adds 300mL, 70 DEG C or so of warm water, stirring
Dissolving, then carries out sensory evaluation.Evaluation group is made up of 10 people, the people of male 3, the people of women 7, under comfortable quiet environment,
Using 6 point-scores, i.e., 1~6 point by weak to strong, the fragrance value of sample, sugariness, acidity, silk slippery, pleasant sensation scale are evaluated,
And obtained result is subjected to local flavor profile analysis, analysis result is shown in Fig. 1.Three sections of products are respectively provided with good fragrance, sweet tea acid ratio
Example is appropriate, and trial test has pleasant feeling.
The study on the stability of the cancer rehabilitation type Medical Nutritional composition of experimental example 2
1st, the stability of product in aqueous
Example 1,2,3 prepares sample 15g respectively, and each 300ml warm water that adds is sufficiently stirred for, in emulsion, standing respectively
24h and 48h observation solution states, the results are shown in Table 6.
| Title | Before standing | Stand 24h | Stand 48h |
| The sample of embodiment 1 | Milkiness state is without layering | Milkiness state is without layering | Milkiness state is without layering |
| The sample of embodiment 2 | Milkiness state is without layering | Milkiness state is without layering | Milkiness state is without layering |
| The sample of embodiment 3 | Milkiness state is without layering | Milkiness state is without layering | Milkiness state is without layering |
Stability of the cancer rehabilitation type Medical Nutritional composition of table 6 in water
2nd, the long term storage stability experiment of product
With reference to《Health food stability test guideline》, Accelerated stability test is carried out, by the gained sample of embodiment 1
Product, sealing packing, 15g/ bags, take 60 bags, are placed under 37 ± 2 DEG C of temperature, the storage requirement of relative humidity RH75 ± 5%, place
0th, 1,2, investigated within 3 months.By GB/T 29602-2013《Solid beverage national standard》Inspection project, to the water of sample
Divide and microbiological indicator carries out periodic detection, the results are shown in Table 7.
Index determining value during the Medical Nutritional composition of 7 embodiment of table 1 is stored
In accelerated experiment 3 months, each physical and chemical index and sanitary index are qualified, illustrate that product met quality in 24 months
Standard.
The immunoregulation effect to And Utilization of CTX-Immunosuppressed-mice of the cancer rehabilitation type Medical Nutritional composition of experimental example 3
Using the gained sample of embodiment 1 as test sample, 180 6-8 week old cleaning grade female BAl BIc/c mouse are taken, are pressed before experiment
Standard diet is raised one week.It is pre- raise one week after by 180 mouse according to body weight be randomly divided into 6 groups (every group 30, wherein 10 use
In carbonic clearance experiment, remaining 20 is served only for detecting other indexs), the respectively medical battalion of Normal group, model group, embodiment 1
Support basic, normal, high 3 dosage groups of product and positive drug control group.
Normal group mouse peritoneal injection 0.2mL physiological saline, other each group mouse peritoneal injection 0.2mL endoxan
(80mg/kg), 1 time a day, for three days on end, manufacture mouse immune suppresses model.Since the 4th day, Normal group and model group
Mouse gavaging 0.2mL physiological saline, the basic, normal, high 3 dosage group mouse of the Medical Nutritional product of embodiment 1 respectively according to dosage 2.0,4.0
Gavaged with 8.0g/kg, the left-handed miaows of positive drug control group mouse gavaging 10.0mg/kg, daily gavage 1 time, continuous 14 days.
1st, carbonic clearance is tested
Last time gavage terminates after rear 24h, the indian ink of 4 times of normal saline dilution of each group mouse equal tail vein injection
Juice, is calculated according to every 10g body weight 0.1mL.Treat that prepared Chinese ink injects, timing immediately.When injecting 2,10min after prepared Chinese ink, respectively from endocanthion
Veniplex 20 μ L of blood sampling, exist side by side and add it to 2mL0.1%Na2CO3In solution.Determined with spectrophotometer at 600nm
OD value, blank control is made with Na2CO3 solution.Mouse is put to death, liver and spleen is taken, organ surface blood is blotted with filter paper
Dirt, weighs.The ability of mouse carbonic clearance is represented with phagocytic index.Phagocytic index a is calculated according to below equation.Analysis result is shown in figure
2。
T check analysis significant differences.* test group and model group significant difference (P are represented<0.05), ## represent with normally
Group and model group difference extremely significantly (P<0.01).Model group is compared with normal group, and endoxan significantly reduces mouse carbonic clearance
Index (P<0.01)；Each test group is compared with model group, the mouse carbonic clearance in the Medical Nutritional compositions-treated group of 3 dosage
Index significantly improves (P<0.05).As a result show that the Medical Nutritional composition in embodiment 1 is remarkably improved mouse immunity.
2nd, periphery routine analysis of blood
After last time gastric infusion 2h, each group mouse (every group 20) eye socket gathers peripheral blood in anticoagulant tube, utilizes
Automatic Blood Cell Analyzer carries out blood routine detection.Analysis result is shown in Table 8.
Each test group blood routine testing result (mean ± SEM) of 8 embodiment of table 1
One-way analysis of variance is carried out to result.# represents that model group has significant difference (P ＜ 0.05), ## with normal group
Represent that model group has pole significant difference (P ＜ 0.01) with normal group, * represents there is significant difference (P between dosage group and normal group
＜ 0.05), * * represent that dosage group has pole significant difference (P ＜ 0.01) with model group.As a result show, through the immune suppression of endoxan
After system, there is pole significant difference in four blood routine indexes of model group and normal group, in notable downward trend.It is basic, normal, high by three
There is pole significant difference in individual dosage group, indices are significantly raised, and illustrate the Medical Nutritional composition in embodiment 1 with model group
It is remarkably improved the immune level of immunosuppressed mice.
The cancer rehabilitation type Medical Nutritional composition of experimental example 4 is to foretasting the influence of crowd
60 cancer rehabilitation phase patients are recruited altogether to carry out foretasting experiment, are randomly divided into test group and control group, every group each 30
Example patient, during testing, subject's habits and customs and eating habit are without changing, and test group takes gained sample in embodiment 2
Product, each 15g, plus 300mL warm water are taken after mixing it with water, and 2 times a day, are taken after the meal respectively at the morning and evening, and control group drinks 300mL after the meal sooner or later
Warm water.30 days test periods, before the 0th day takes, the 31st day, enter row index collection.MAIN OUTCOME MEASURES includes：Human body
Composition, defecation situation, part physiochemical indice experimental result are as follows：
1st, human body component
Using human body component analyzer, body weight, Fat distribution, the muscle weight index of 60 subjects is collected, is as a result seen
Table -9.
The human body component index (mean ± SEM) of the cancer rehabilitation phase of table -9 subject
One-way analysis of variance is carried out to the data obtained, * represents to there is significant difference (P ＜ with the 0th day data on the 31st day
0.05).As a result show, the 31st day body weight values of control group are without significantly sexually revising (P ＞ 0.05), and the test group body weight of the 31st day is notable
Increase (P ＜ 0.05)；The 31st day fat mass of control group, test group there are no significant change (P ＞ 0.05)；The 31st day flesh of control group
Meat amount is without significantly sexually revising (P ＞ 0.05), and test group muscle mass conspicuousness increases (P ＜ 0.05).As a result the cancer of embodiment 2 is shown
Rehabilitation type Medical Nutritional composition can significantly improve the nutrition condition of cancer patient, improve body weight, increase muscle mass, effectively alleviate
Cachexia.
2nd, defecation situation
Collect 30 subject's defecation feedbacks of test group.There is constipation situation before wherein 12 subjects, it is average
Infrequent defecation is 3-4 days, after Medical Nutritional composition described in embodiment 2 is taken 7-10 days, and average infrequent defecation shorten to 1-3
My god；There is a situation where that infrequent defecation is short after the meal, daily defecation frequency is more before wherein 10 subjects, taking the institute of embodiment 2
Medical Nutritional composition is stated after 10-18 days, defecation time was extended for 1.5-2.5 small by original 0.5-1 after the meal hours after the meal
When, average daily defecation frequency is shorten to 1-2 times by original 2-3 times.Show that Medical Nutritional composition can be two-way described in embodiment 2
Constipation, diarrhoea are adjusted, improves intestinal absorption.
3rd, physiochemical indice
Respectively the 0th day and the 31st day, whole blood is gathered, albumin, prealbumin, hemoglobin, four, red blood cell is collected
Index, the results are shown in Table -10.
The cancer rehabilitation phase of table -10 blood samples of patients index (mean ± SEM)
One-way analysis of variance is carried out to the data obtained, * represents to there is significant difference (P ＜ with the 0th day data on the 31st day
0.05), * * represent to there is pole significant difference (P ＜ 0.01) with the 0th day data on the 31st day.As a result show, control group the 31st day
Albumin, prealbumin, hemoglobin, red blood cell there are no significant change (P ＞ 0.05)；The test group albumin of the 31st day,
Prealbumin, hemoglobin body weight significantly increase (P ＜ 0.05), and red blood cell extremely significantly increases.As a result show, the cancer of embodiment 2
Rehabilitation type Medical Nutritional product can significantly improve cancer patient's nutrition condition and Status of Anemia.
Claims (8)
1. a kind of cancer rehabilitation type Medical Nutritional composition, it is characterised in that contain for cancer rehabilitation phase syndrome there is provided one kind
Medical Nutritional product including nutrition component, herbal component, immunological regulation component, gastrointestinal regulation component.
2. Medical Nutritional composition according to claim 1, it is characterised in that the nutrition component include protein source,
Fat source and carbohydrate source, in terms of composition gross mass, the protein in Medical Nutritional composition accounts for 10-35%, lipid
2-20% is accounted for, carbohydrate accounts for 40-55%.
3. Medical Nutritional composition according to claim 2, it is characterised in that protein is selected from lactalbumin, collagen egg
One or more in white；One or more of the fat in MCT Oil, fish oil, linseed oil；Carbon water
One or more of the compound in inulin, polydextrose, xylo-oligosaccharide.
4. Medical Nutritional composition according to claim 1, it is characterised in that in terms of composition gross mass, ginseng is accounted for
0.5-10%, Cordyceps militaris accounts for 0.5-8%, and Tea Polyphenols accounts for 0.5-6%, and omega-3 unsaturated fatty acid accounts for 5-20%, biologically active peptide
Account for 5-20%, the one kind of the biologically active peptide in cordyceps sinensis peptide, ginseng peptide, collagen peptide, silkworm chrysalis peptide, donkey-hide gelatin peptide, sea cucumber peptide
Or it is a variety of, glutamine accounts for 2-10%, and MCT Oil accounts for 1-6%, and branched-chain amino acid accounts for 1-6%, β-yeast Portugal
Glycan accounts for 0.5-5%, and inulin accounts for 3-10%.
5. Medical Nutritional composition according to claim 4, it is characterised in that the ginseng, Cordyceps militaris, biological polypeptide,
Linseed oil, fish oil, MCT Oil be handled by encapsulation process obtained by microcapsule powder, microencapsulation is with β-ring
One or more in dextrin, chitosan, maltodextrin, Arabic gum, polyvinyl alcohol, PLA are capsule material.
6. Medical Nutritional composition according to claim 4, it is characterised in that the Cordyceps militaris, linseed oil-bound distemper, fish oil
Powder, biological polypeptide powder are by the instant powder obtained by instant PROCESS FOR TREATMENT.
7. according to any described Medical Nutritional compositions of claim 1-6, it is characterised in that the formulation of the alimentation composition
For pulvis, granule, tablet, oral liquid.
8. prepare the method for the Medical Nutritional composition described in claim 1, it is characterised in that the preparation method is：Will be each
Bulk drug is crushed, and part material will be added needed for preparations shaping after all raw materials afterwards through microencapsulation or instant PROCESS FOR TREATMENT
Auxiliary material, clinically suitable various preparations are made according to pharmaceutical preparation conventional method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710545346.3A CN107242551A (en) | 2017-07-06 | 2017-07-06 | A kind of cancer rehabilitation type Medical Nutritional composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710545346.3A CN107242551A (en) | 2017-07-06 | 2017-07-06 | A kind of cancer rehabilitation type Medical Nutritional composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107242551A true CN107242551A (en) | 2017-10-13 |
Family
ID=60013911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710545346.3A Pending CN107242551A (en) | 2017-07-06 | 2017-07-06 | A kind of cancer rehabilitation type Medical Nutritional composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107242551A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108813622A (en) * | 2018-07-04 | 2018-11-16 | 张斌 | Preparation method of sugar-free starch-free food for assisting chemotherapy rehabilitation of cancer patients |
| CN110353274A (en) * | 2019-08-16 | 2019-10-22 | 深圳市德福康泰生物科技有限公司 | A kind of nutrient solution and preparation method thereof facilitating tumor patient postoperative rehabilitation |
| CN113575950A (en) * | 2021-08-06 | 2021-11-02 | 徐文红 | A nutritional product with adjuvant rehabilitation effect for radiotherapy and chemotherapy of cancer patients |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104605353A (en) * | 2015-01-27 | 2015-05-13 | 南阳市新天地生物科技有限公司 | Formula food suitable for being eaten by tumor patients after operation and preparation method of formula food |
| CN105410932A (en) * | 2015-11-03 | 2016-03-23 | 北京赛升药业股份有限公司 | Tumor immunity type nutritional composition and application thereof |
| CN106858617A (en) * | 2017-01-18 | 2017-06-20 | 恩施硒域传奇健康管理有限公司 | A kind of cancer convalescence full nutrition formula food |
-
2017
- 2017-07-06 CN CN201710545346.3A patent/CN107242551A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104605353A (en) * | 2015-01-27 | 2015-05-13 | 南阳市新天地生物科技有限公司 | Formula food suitable for being eaten by tumor patients after operation and preparation method of formula food |
| CN105410932A (en) * | 2015-11-03 | 2016-03-23 | 北京赛升药业股份有限公司 | Tumor immunity type nutritional composition and application thereof |
| CN106858617A (en) * | 2017-01-18 | 2017-06-20 | 恩施硒域传奇健康管理有限公司 | A kind of cancer convalescence full nutrition formula food |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108813622A (en) * | 2018-07-04 | 2018-11-16 | 张斌 | Preparation method of sugar-free starch-free food for assisting chemotherapy rehabilitation of cancer patients |
| CN110353274A (en) * | 2019-08-16 | 2019-10-22 | 深圳市德福康泰生物科技有限公司 | A kind of nutrient solution and preparation method thereof facilitating tumor patient postoperative rehabilitation |
| CN113575950A (en) * | 2021-08-06 | 2021-11-02 | 徐文红 | A nutritional product with adjuvant rehabilitation effect for radiotherapy and chemotherapy of cancer patients |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
| CN102670864B (en) | Medicine composition with antioxidant function for treating cardiovascular and cerebrovascular diseases and sugar diabetes | |
| CN106942748A (en) | A kind of female acyesis tailored version clinical nutrition formula and preparation method thereof | |
| JP2008174539A (en) | Healthy and functional food for obesity patient using purple-colored potato | |
| CN107440120A (en) | A kind of children's monophagia and anorexia tailored version clinical nutrition formula particular about food and preparation method thereof | |
| CN106605744A (en) | Composition capable of reducing fat, slimming, expelling toxin and beautifying, as well as preparation method thereof | |
| CN102240318B (en) | Preparation method and analysis method of traditional Chinese medicine for tonifying qi and increasing breast milk | |
| CN102258679B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN102600423A (en) | Preparation method of Chinese medicine for treating hepatic fibrosis | |
| CN107242551A (en) | A kind of cancer rehabilitation type Medical Nutritional composition and preparation method thereof | |
| CN105079309A (en) | Composition for relaxing bowels to relieve constipation | |
| ES2719277T3 (en) | Composition of purified soluble mannan for food supplements and methods of use thereof | |
| CN103610054A (en) | Healthcare food with effects of reducing weight and facilitating feces excretion and preparation method thereof | |
| CN103584083B (en) | A kind of enteral nutrition preparation for gestational diabetes mellitus women and its production and use | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN104544130A (en) | Soft capsule for improving alimentary anemia and preparation method of soft capsule | |
| CN102048841B (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| JP2003252785A (en) | Western ginseng mixture and its manufacturing method | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN102824593A (en) | Chinese patent medicine for treating chronic renal failure | |
| CN113952419B (en) | Pharmaceutical composition for chronic renal failure and preparation method and application thereof | |
| CN101336705B (en) | Health food and its preparation method | |
| CN106729147A (en) | Fortifying spleen and promoting digestion for promoting children's appetite | |
| CN102784230B (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN102048890A (en) | Traditional Chinese medicine composition with galactagogue effect and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171013 |
|
| WD01 | Invention patent application deemed withdrawn after publication |